Cochrane · systematic review · CD011323
Antiretroviral interventions for preventing breast milk transmission of HIV
White, AB, Mirjahangir, JF, Horvath, H, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
77
current version
GRADE rated
77
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 14 · 18.2%Low 31 · 40.3%Moderate 29 · 37.7%High 3 · 3.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
An extended NVP regimen administered to infants for 14 weeks compared to sdNVP plus ZDV (1week) for prevention of breastfeeding transmission
Population: Breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.56 [0.41, 0.76] | 1 study · 2019 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.72 [0.5, 1.05] | 1 study · 2019 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.69 [0.55, 0.87] | 1 study · 2019 participants | High |
HIV Transmission at 24 months among those uninfected at birth11 An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.6 [0.46, 0.78] | 1 study · 1129 participants | Moderate Downgraded: imprecision |
Infant Mortality at 24 months among those uninfected at birth An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.74 [0.54, 1.01] | 1 study · 1266 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 24 months among those uninfected at birth11 An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | HR 0.71 [0.58, 0.87] | 1 study · 1129 participants | Moderate Downgraded: imprecision |
Infants with possible related Severe Adverse Events ‐ 24 months11 An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | RR 1.06 [0.7, 1.59] | 1 study · 2019 participants | Very low Downgraded: imprecision |
Infants with Probably Related Severe Adverse Events11 An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) | RR 2.96 [0.6, 14.64] | 1 study · 2019 participants | Very low Downgraded: imprecision |
An extended NVP plus ZDV regimen administered to infants for 14 weeks compared to sdNVP plus ZDV (1 week) for prevention of breastfeeding transmission
Population: Breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.65 [0.48, 0.88] | 1 study · 2000 participants | Moderate Downgraded: imprecision |
Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.66 [0.46, 0.96] | 1 study · 2000 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.72 [0.57, 0.9] | 1 study · 2000 participants | High |
HIV Transmission at 24 months among those uninfected at birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.65 [0.5, 0.85] | 1 study · 1123 participants | Moderate Downgraded: imprecision |
Infant Mortality at 24 months among those uninfected at birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.73 [0.53, 1] | 1 study · 1207 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 24 months among those uninfected at birth An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | HR 0.73 [0.6, 0.9] | 1 study · 1123 participants | Moderate Downgraded: imprecision |
Infants with any Severe Adverse Events An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | RR 1.75 [1.22, 2.53] | 1 study · 2000 participants | Very low Downgraded: imprecision |
Infants with Probably Related Severe Adverse Events An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) | RR 3.02 [0.61, 14.92] | 1 study · 2000 participants | Very low Downgraded: imprecision |
An extended NVP plus ZDV dual regimen administered to infants for 14 weeks compared to an extended NVP regimen administered to infants for 14 weeks
Population: Breastfeeding infants of HIV‐infected mothers1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 1.23 [0.83, 1.81] | 1 study · 2013 participants | Moderate Downgraded: imprecision |
Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 0.91 [0.61, 1.36] | 1 study · 2013 participants | Moderate Downgraded: imprecision |
HIV Transmission at 24 months among those uninfected at birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 1.04 [0.71, 1.51] | 1 study · 1122 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 1.09 [0.82, 1.44] | 1 study · 2013 participants | Moderate Downgraded: imprecision |
Infant Mortality at 24 months among those uninfected at birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 0.91 [0.61, 1.36] | 1 study · 1273 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 24 months among those uninfected at birth An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | HR 1 [0.75, 1.34] | 1 study · 1122 participants | Moderate Downgraded: imprecision |
Infants with any Severe Adverse Events An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | RR 1.66 [1.16, 2.37] | 1 study · 2013 participants | Low Downgraded: imprecision |
Infants with Probably Related Severe Adverse Events An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants | RR 1.02 [0.33, 3.15] | 1 study · 2013 participants | Very low Downgraded: imprecision |
An extended NVP regimen administered to infants for 6 weeks compared to sdNVP for prevention of breastfeeding transmission
Population: Breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission at 6 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.78 [0.57, 1.07] | 1 study · 1887 participants | Moderate Downgraded: imprecision |
Infant Mortality at 6 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.47 [0.26, 0.84] | 1 study · 1887 participants | Low Downgraded: imprecision |
HIV Transmission or Death at 6 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.72 [0.54, 0.95] | 1 study · 1887 participants | Moderate Downgraded: imprecision |
Genotypic Resistance to NVP among Ugandan infants HIV‐infected at 6 weeks ViroSeq An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 1.68 [1.09, 2.6] | 1 study · 49 participants | Low Downgraded: imprecision |
Persistance of Genotypic Resistance to NVP at 6 months among Ugandan infants found to be resistant at 6 weeks ViroSeq An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 4.38 [1.05, 18.28] | 1 study · 13 participants | Low Downgraded: imprecision |
Genotypic Resistance to NVP among Indian infants HIV‐infected in utero or through peripartum/early‐breastfeeding transmission Standard Population Sequencing An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 2.42 [1.47, 3.97] | 1 study · 41 participants | Low Downgraded: imprecision |
Genotypic Resistance to NVP among Indian infants HIV‐infected through late breastfeeding Standard Population Sequencing An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 1.03 [0.2, 5.33] | 1 study · 33 participants | Low Downgraded: imprecision |
HIV Transmission at 12 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.89 [0.67, 1.17] | 1 study · 1813 participants | Moderate Downgraded: imprecision |
Infant Mortality at 12 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.53 [0.32, 0.85] | 1 study · 2350 participants | Moderate Downgraded: imprecision |
HIV Transmission or Death at 12 months among those whose HIV diagnostic testing was negative within 7 days of birth An extended NVP regimen administered to infants for 6 weeks vs sdNVP | RR 0.79 [0.61, 1.01] | 1 study · 1883 participants | Moderate Downgraded: imprecision |
An extended ZDV regimen administered to breastfeeding infants for 6 months for prevention of breastfeeding transmission
Population: breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission at 7 months among those whose HIV diagnostic testing was negative at one month after birth | HR 4.77 [2.22, 10.24] | 1 study · 1123 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 18 months | HR 0.73 [0.49, 1.08] | 1 study · 1179 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
HIV Transmission or Death at 18 months among those whose HIV diagnostic testing was negative at one month after birth | HR 1.21 [0.81, 1.8] | 1 study · 1123 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infants with Grade 3/4 Signs or Symptoms | RR 0.74 [0.56, 0.98] | 1 study · 1179 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infants with Grade 3/4 Laboratory Abnormalities | RR 1.7 [1.33, 2.17] | 1 study · 1179 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infant with Toxicity Events leading to cessation of ZDV | RR 5.53 [2.85, 10.74] | 1 study · 1179 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
An extended ZDV/3TC/LPV/r regimen administered to mothers compared to an extended ZDV/3TC/ABC administered to mothers for prevention of breastfeeding transmission
Population: HIV‐infected mothers and their breastfeeding infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 0.21 [0.01, 4.3] | 1 study · 548 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 6 months An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 1.05 [0.37, 2.95] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV Transmission or Death at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 0.81 [0.3, 2.14] | 1 study · 548 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infants with Grade 3/4 Severe Adverse Events An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 1.13 [0.93, 1.37] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Maternal Mortality at 6 months An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 0.35 [0.01, 8.44] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mothers with any Grade 3/4 Severe Adverse Event An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 0.79 [0.51, 1.21] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mothers with Severe Adverse Events Requiring Treatment Modification An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers | RR 0.89 [0.3, 2.61] | 1 study · 560 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
An extended ZDV/3TC/LPV/r regimen administered to mothers compared to short course ZDV (intrapartum ZDV/3TC/sdNVP) for preventing breastfeeding transmission
Population: HIV‐infected mothers and their breastfeeding infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 6 months among those whose diagnostic testing was negative at 6 weeks after birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.36 [0.13, 1.02] | 1 study · 597 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission at 12 months among those whose diagnostic testing was negative at 6 weeks after birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.4 [0.16, 0.96] | 1 study · 597 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 6 months An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.88 [0.36, 2.11] | 1 study · 624 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 12 months An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.94 [0.48, 1.85] | 1 study · 624 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission or Death at 6 months among those whose HIV diagnostic testing was negative at 6 weeks after birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.61 [0.3, 1.24] | 1 study · 599 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission or Death at 12 months among those whose HIV diagnostic testing was negative at 6 weeks after birth An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | HR 0.52 [0.28, 0.93] | 1 study · 599 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Maternal Grade 3/4 Severe Adverse Events An extended ZDV/3TC/LPV/r regimen administered to mothers vs short course ZDV (intrapartum ZDV/3TC/sdNVP) | RR 1.19 [0.83, 1.7] | 1 study · 824 participants | Very low Downgraded: imprecision, inconsistency |
An extended antiretroviral regimen administered to mothers for 28 weeks compared to 1 week of antiretroviral prophylaxis for transmission during breastfeeding
Population: HIV‐infected mothers and their breastfeeding infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended antiretroviral regimen administered to mothers for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.52 [0.3, 0.89] | 1 study · 1435 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended antiretroviral regimen administered to mothers for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.67 [0.31, 1.45] | 1 study · 1517 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks An extended antiretroviral regimen administered to mothers for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.61 [0.38, 0.96] | 1 study · 1435 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infants with Severe Adverse Events An extended antiretroviral regimen administered to mothers for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 1.11 [0.86, 8.45] | 1 study · 1517 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mothers with Severe Adverse Events An extended antiretroviral regimen administered to mothers for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 2.19 [1.2, 4] | 1 study · 1517 participants | Low Downgraded: imprecision |
An extended NVP regimen administered to infants for 28 weeks compared to 1 week of antiretroviral prophylaxis for preventing transmission during breastfeeding
Population: Breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.29 [0.15, 0.56] | 1 study · 1447 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.62 [0.28, 1.35] | 1 study · 1520 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 0.38 [0.22, 0.65] | 1 study · 1447 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infants with Severe Adverse Events An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis | RR 1.25 [0.97, 1.61] | 1 study · 1520 participants | Low Downgraded: imprecision |
A once‐daily NVP regimen administered for 6 months compared to a once‐daily NVP regimen administered for 6 weeks for prevention of breastfeeding transmission of HIV
Population: Breastfeeding infants of HIV‐infected mothers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 12 months among infants whose HIV diagnostic testing was negative within 6 weeks of birth and whose mothers were not on HAART A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.65 [0.33, 1.28] | 1 study · 1078 participants | Low Downgraded: imprecision |
HIV transmission at 12 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.66 [0.34, 1.27] | 1 study · 1512 participants | Low Downgraded: imprecision |
Infant mortality at 12 months among all those whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.75 [0.41, 1.35] | 1 study · 1522 participants | Low Downgraded: imprecision |
HIV transmission or death at 12 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.66 [0.42, 1.05] | 1 study · 1522 participants | Moderate Downgraded: imprecision |
Infants with Severe Adverse Events A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | RR 1 [0.95, 1.05] | 1 study · 1519 participants | High |
HIV transmission at 6 months among infants whose HIV diagnostic testing was negative within 6 weeks of birth and whose mothers were not on HAART A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.41 [0.18, 0.9] | 1 study · 1078 participants | Low Downgraded: imprecision |
HIV transmission at 6 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.46 [0.21, 0.99] | 1 study · 1512 participants | Low Downgraded: imprecision |
Infant mortality at 6 months among all those whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.44 [0.21, 0.95] | 1 study · 1522 participants | Low Downgraded: imprecision |
HIV transmission or death at 6 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered | HR 0.7 [0.38, 1.31] | 1 study · 1522 participants | Low Downgraded: imprecision |
An extended antiretroviral regimen administered to mothers for 28 weeks compared to an extended NVP regimen administered to infants for 28 weeks for preventing transmission during breastfeeding
Population: HIV‐infected mothers and their breastfeeding infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants | RR 1.78 [0.88, 3.59] | 1 study · 1618 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants | RR 1.09 [0.48, 2.47] | 1 study · 1701 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants | RR 1.6 [0.91, 2.82] | 1 study · 1618 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infants with Severe Adverse Events An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants | RR 0.89 [0.71, 1.12] | 1 study · 1701 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mothers with Severe Adverse Events An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants | RR 2.8 [1.53, 5.11] | 1 study · 1701 participants | Low Downgraded: risk of bias, imprecision, inconsistency |